Get the Stockscreener App
1.64
4.09%
-0.07
Macrogenics Inc stock is traded at $1.64, with a volume of 315.21K.
It is down -4.09% in the last 24 hours and up +30.16% over the past month.
See More
Previous Close:
$1.71
Open:
$1.7
24h Volume:
315.21K
Relative Volume:
0.41
Market Cap:
$87.70M
Revenue:
$139.77M
Net Income/Loss:
$-97.62M
P/E Ratio:
-1.038
EPS:
-1.58
Net Cash Flow:
$-61.71M
1W Performance:
+17.99%
1M Performance:
+30.16%
6M Performance:
-53.41%
1Y Performance:
-88.74%
1-Day Range:
$1.575
$1.74
1-Week Range:
$1.335
$1.81
52-Week Range:
$0.9897
$16.44
Macrogenics Inc Stock (MGNX) Company Profile
Name
Macrogenics Inc
Sector
Industry
Phone
301-251-5172
Address
9704 MEDICAL CENTER DRIVE, Rockville, MD
Compare MGNX with other stocks
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
MGNX
Macrogenics Inc
|
1.64 | 87.70M | 139.77M | -97.62M | -61.71M | -1.58 |
|
VRTX
Vertex Pharmaceuticals Inc
|
496.49 | 122.76B | 11.02B | -535.60M | -978.00M | -2.20 |
|
REGN
Regeneron Pharmaceuticals Inc
|
610.86 | 61.38B | 14.20B | 4.41B | 3.54B | 38.28 |
|
ARGX
Argen X Se Adr
|
620.97 | 36.37B | 2.19B | 833.04M | -1.28B | 12.71 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
254.85 | 30.12B | 2.25B | -278.16M | -42.59M | -2.17 |
|
ONC
Beigene Ltd Adr
|
249.46 | 24.70B | 3.81B | -644.79M | -669.77M | -6.24 |
Macrogenics Inc Stock (MGNX) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| Nov-07-24 | Downgrade | JMP Securities | Mkt Outperform → Mkt Perform |
| Aug-01-24 | Downgrade | BTIG Research | Buy → Neutral |
| Jul-31-24 | Downgrade | B. Riley Securities | Buy → Neutral |
| Jul-31-24 | Downgrade | Guggenheim | Buy → Neutral |
| May-10-24 | Downgrade | BMO Capital Markets | Outperform → Market Perform |
| May-10-24 | Downgrade | Stifel | Buy → Hold |
| May-10-24 | Downgrade | TD Cowen | Buy → Hold |
| Apr-26-24 | Initiated | B. Riley Securities | Buy |
| Apr-09-24 | Upgrade | TD Cowen | Hold → Buy |
| Mar-04-24 | Reiterated | BTIG Research | Buy |
| Feb-14-24 | Downgrade | H.C. Wainwright | Buy → Neutral |
| Dec-20-23 | Upgrade | Citigroup | Neutral → Buy |
| Nov-07-23 | Upgrade | Guggenheim | Neutral → Buy |
| Mar-17-23 | Downgrade | Guggenheim | Buy → Neutral |
| Nov-22-22 | Downgrade | Cowen | Outperform → Market Perform |
| Nov-14-22 | Upgrade | BMO Capital Markets | Market Perform → Outperform |
| Jul-18-22 | Downgrade | SMBC Nikko | Outperform → Neutral |
| Jul-11-22 | Downgrade | BMO Capital Markets | Outperform → Market Perform |
| May-04-22 | Downgrade | Guggenheim | Buy → Neutral |
| Feb-28-22 | Upgrade | Citigroup | Neutral → Buy |
| Feb-11-22 | Initiated | BMO Capital Markets | Outperform |
| Feb-04-22 | Initiated | SMBC Nikko | Outperform |
| Nov-17-21 | Resumed | Guggenheim | Buy |
| Oct-19-21 | Initiated | JMP Securities | Mkt Outperform |
| Oct-15-21 | Resumed | BTIG Research | Buy |
| Apr-26-21 | Resumed | Credit Suisse | Outperform |
| Mar-12-21 | Upgrade | Barclays | Underweight → Overweight |
| Dec-22-20 | Resumed | H.C. Wainwright | Buy |
| Aug-03-20 | Downgrade | Citigroup | Buy → Neutral |
| Jun-01-20 | Upgrade | Guggenheim | Neutral → Buy |
| May-26-20 | Reiterated | H.C. Wainwright | Buy |
| Mar-04-20 | Initiated | Barclays | Underweight |
| Dec-19-19 | Initiated | Cantor Fitzgerald | Overweight |
| Dec-18-19 | Initiated | Cantor Fitzgerald | Overweight |
| Nov-21-19 | Downgrade | Morgan Stanley | Equal-Weight → Underweight |
| Nov-20-19 | Resumed | Guggenheim | Neutral |
| May-03-19 | Upgrade | Wedbush | Neutral → Outperform |
| Apr-12-19 | Initiated | Guggenheim | Neutral |
| Feb-07-19 | Upgrade | Citigroup | Sell → Buy |
| Feb-07-19 | Downgrade | Wedbush | Outperform → Neutral |
| Feb-06-19 | Upgrade | Raymond James | Underperform → Mkt Perform |
| Feb-04-19 | Downgrade | Citigroup | Neutral → Sell |
| Dec-10-18 | Downgrade | Raymond James | Outperform → Underperform |
| Sep-10-18 | Resumed | BTIG Research | Buy |
| May-31-18 | Initiated | Evercore ISI | Outperform |
| Mar-05-18 | Initiated | H.C. Wainwright | Buy |
| Mar-31-17 | Initiated | Raymond James | Outperform |
View All
Macrogenics Inc Stock (MGNX) Latest News
Press Release Distribution & PR Platform - ACCESS Newswire
MGNXMacroGenics Provides Update on Corporate Progress and 2024 Financial Results - ADVFN
The MGNX Stock Puzzle: Unraveling Macrogenics Inc’s Fluctuating Performance - investchronicle.com
MacroGenics Provides Update on Corporate Progress and 1st Quarter 2017 Financial Results - ADVFN
MacroGenics Provides Update on Corporate Progress and 2024 Financial Results - ADVFN
Form 10-QQuarterly report [Sections 13 or 15(d)] - ADVFN
MacroGenics Provides Update on Corporate Progress and First Quarter 2019 Financial Results - ADVFN
MacroGenics Provides Update on Corporate Progress and Third Quarter 2021 Financial Results - ADVFN
MacroGenics Provides Update on Corporate Progress and Third Quarter 2015 Financial Results - ADVFN
Investor Expectations to Drive Momentum within LPL Financial, Comcast, MacroGenics, Wayfair, Masimo, and Big Lots — Discove... - ADVFN
MacroGenics Provides Update on Corporate Progress and Second Quarter 2019 Financial Results - ADVFN
MacroGenics Provides Update on Corporate Progress and Second Quarter 2023 Financial Results - ADVFN
MacroGenics Provides Update on Corporate Progress and Second Quarter 2021 Financial Results - ADVFN
Comparing Ensysce Biosciences (NASDAQ:ENSC) & MacroGenics (NASDAQ:MGNX) - Defense World
MacroGenics, Inc. (NASDAQ:MGNX) Receives $7.38 Average Price Target from Analysts - Defense World
MacroGenics, Inc. Sued for Securities Law ViolationsContact the DJS Law Group to Discuss Your RightsMGNX - marketscreener.com
American Century Companies Inc. Buys Shares of 11,743 MacroGenics, Inc. (NASDAQ:MGNX) - Defense World
MacroGenics, Inc. (NASDAQ:MGNX) Looks Inexpensive After Falling 42% But Perhaps Not Attractive Enough - simplywall.st
Wellington Management Group LLP Acquires 16,717 Shares of MacroGenics, Inc. (NASDAQ:MGNX) - Defense World
ATTENTION MGNX SHAREHOLDERS: Investors who lost money on MacroGenics, Inc. are urged to contact Levi & Korsinsky about an ongoing investigation - ACCESS Newswire
Next Generation Immunotherapies Market Growth Projections - openPR.com
MGNX Deadline in 5 Days: Kessler Topaz Meltzer & Check, LLP Reminds MacroGenics, Inc. (MGNX) Investors of Filing Deadline in Class Action Lawsuit - marketscreener.com
Class Action Filed Against MacroGenics, Inc. (MGNX) Seeking Recovery for InvestorsContact Levi & Korsinsky - ACCESS Newswire
MGNX INVESTOR ALERT: Bronstein, Gewirtz and Grossman, LLC Announces that MacroGenics, Inc. Stockholders Have Opportunity to Lead Class Action Lawsuit! - ACCESS Newswire
MGNX INVESTOR ALERT: Bronstein, Gewirtz and Grossman, LLC Announces that MacroGenics, Inc. Shareholders with Losses Have Opportunity to Lead Class Action Lawsuit! - ACCESS Newswire
MGNX INVESTOR ALERT: Bronstein, Gewirtz and Grossman, LLC Announces that MacroGenics, Inc. Shareholders with Substantial Losses Have Opportunity to Lead Class Action Lawsuit! - ACCESS Newswire
Lost Money on MacroGenics, Inc.(MGNX)? Join Class Action Suit Seeking RecoveryContact Levi & Korsinsky - ACCESS Newswire
908 Devices Leads These 3 Penny Stocks To Consider - simplywall.st
MGNX INVESTOR ALERT: Bronstein, Gewirtz and Grossman, LLC Announces that MacroGenics, Inc. Stockholders with Substantial Losses Have Opportunity to Lead Class Action Lawsuit! - ACCESS Newswire
ATTENTION MacroGenics, Inc. Investors: You May Have Been Affected by Fraud- Contact Levi & Korsinsky to Discuss Your Rights - ACCESS Newswire
Levi & Korsinsky Notifies Shareholders of MacroGenics, Inc. (MGNX) of a Class Action Lawsuit and an Upcoming Deadline - ACCESS Newswire
MacroGenics (MGNX) Halts Prostate Cancer Trial After Fatal Adverse Events, Investor SuitHagens Berman - ACCESS Newswire
Levi & Korsinsky Reminds Shareholders of a Lead Plaintiff Deadline of September 24, 2024 in MacroGenics, Inc. LawsuitMGNX - ACCESS Newswire
MacroGenics (MGNX) Loses -48.74% in 4 Weeks, Here's Why a Trend Reversal May be Around the Corner - Yahoo Finance
Levi & Korsinsky Reminds MacroGenics Investors of the Pending Class Action Lawsuit with a Lead Plaintiff Deadline of September 24, 2024MGNX - ACCESS Newswire
MacroGenics, Inc. (NASDAQ:MGNX) Shares Purchased by Charles Schwab Investment Management Inc. - Defense World
Bank of New York Mellon Corp Has $540,000 Stock Holdings in MacroGenics, Inc. (NASDAQ:MGNX) - Defense World
HC Wainwright Increases Earnings Estimates for MacroGenics - Defense World
Macrogenics Inc Stock (MGNX) Financials Data
Revenue
Net Income
Cash Flow
EPS
0.19%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):